4 research outputs found
Phase i trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
BACKGROUND: This phase I dose-finding trial evaluated safety, efficacy and pharmacokinetics of axitinib, a potent and selective secondgeneration
inhibitor of vascular endothelial growth factor receptors, combined with platinum doublets in patients with advanced
non-small cell lung cancer (NSCLC) and other solid tumours.
METHODS: In all, 49 patients received axitinib 5mg twice daily (b.i.d.) with paclitaxel/carboplatin or gemcitabine/cisplatin in 3-week
cycles. Following determination of the maximum tolerated dose, a squamous cell NSCLC expansion cohort was enroled and
received axitinib 5mg b.i.d. with paclitaxel/carboplatin.
RESULTS: Two patients experienced dose-limiting toxicities: febrile neutropenia (n¼1) in the paclitaxel/carboplatin cohort and fatigue
(n¼1) in the gemcitabine/cisplatin cohort. Common nonhaematologic treatment-related adverse events were hypertension (36.7%),
diarrhoea (34.7%) and fatigue (28.6%). No gradeX3 haemoptysis occurred among 12 patients with squamous cell NSCLC. The
objective response rate was 37.0% for patients receiving axitinib/paclitaxel/carboplatin (n¼27) and 23.8% for patients receiving
axitinib/gemcitabine/cisplatin (n¼21). Pharmacokinetics of axitinib and chemotherapeutic agents were similar when administered
alone or in combination.
CONCLUSION: Axitinib 5mg b.i.d. may be combined with standard paclitaxel/carboplatin or gemcitabine/cisplatin regimens without
evidence of overt drug–drug interactions. Both combinations demonstrated clinical efficacy and were well tolerated.This study was sponsored by Pfizer Inc. Support was provided in
part by National Institutes of Health grant P30 CA006927 to the
Fox Chase Cancer Center. We thank the patients who participated
in this study and the physicians who referred them, as well as the
study coordinators and data managers, Shelley Mayfield and Carol
Martins at Pfizer Inc. for support of the study conduct, and Gamal
ElSawah, Pfizer Medical Affairs, for his review of the manuscript.
Medical writing support was provided by Joanna Bloom, of UBC
Scientific Solutions (Southport, CT, USA) and Christine Arris at
ACUMED (Tytherington, UK) and was funded by Pfizer In